C018 | OVERALL SURVIVAL AND DURATION OF TREATMENT IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS RECEIVING AVAPRITINIB VERSUS MIDOSTAURIN OR BEST AVAILABLE THERAPY IN A REAL-WORLD SETTING

Introduction In this retrospective study of the efficacy of avapritinib, a selective KIT D816V inhibitor, in adults with advanced systemic mastocytosis (AdvSM), we compared overall survival (OS) and duration of treatment (DOT) in patients treated with either avapritinib in the PATHFINDER (NCT035806...

詳細記述

書誌詳細

出版年:	Haematologica
主要な著者:	A. M. Vannucchi, A. Reiter, J. Gotlib, I. Álvarez-Twose, D. H. Radia, J. Luebke, P. J. Bobbili, A. Wang, S. Dimitrijević, E. Sullivan, J. Schwaab, I. A. Galinsky, C. Perkins, W. R. Sperr, P. Sriskandarajah, M. Mohan, T. Badu, M. S. Duh, P. Valent
フォーマット:	論文
言語:	英語
出版事項:	Ferrata Storti Foundation 2025-09-01
オンライン･アクセス:	https://haematologica.org/article/view/12882